PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination
Journal of Clinical Investigation · 2023
DOI: 10.1172/jci160456 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2023. Verfasst von Xinfang Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: B7-H1 Antigen, Tumor Escape. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
Programmed death-ligand 1 (PD-L1), a critical immune checkpoint ligand, is a transmembrane protein synthesized in the endoplasmic reticulum of tumor cells and transported to the plasma membrane to interact with programmed death 1 (PD-1) expressed on T cell surface. This interaction delivers coinhibitory signals to T cells, thereby suppressing their function and allowing evasion of antitumor immunity. Most companion or complementary diagnostic devices for assessing PD-L1 expression levels in tumor cells used in the clinic or in clinical trials require membranous staining. However, the mechanism driving PD-L1 translocation to the plasma membrane after de novo synthesis is poorly understood. Herein, we showed that mind bomb homolog 2 (MIB2) is required for PD-L1 transportation from the trans-Golgi network (TGN) to the plasma membrane of cancer cells. MIB2 deficiency led to fewer PD-L1 proteins on the tumor cell surface and promoted antitumor immunity in mice. Mechanistically, MIB2 catalyzed nonproteolytic K63-linked ubiquitination of PD-L1, facilitating PD-L1 trafficking through Ras-associated binding 8-mediated (RAB8-mediated) exocytosis from the TGN to the plasma membrane, where it bound PD-1 extrinsically to prevent tumor cell killing by T cells. Our findings demonstrate that nonproteolytic ubiquitination of PD-L1 by MIB2 is required for its transportation to the plasma membrane and tumor cell immune evasion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
- Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Department of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Clinical Center for Gene Diagnosis and Therapy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
- Department of Molecular Cell Biology, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
- School of Transportation, Southeast University, Nanjing, Jiangsu, China.
Förderung
- NCI NIH HHS
- NIH HHS
- Cancer Prevention and Research Institute of Texas
Zitieren
APA
Yu, X., Li, W., Liu, H., Wang, X., Coarfa, C., Cheng, C., Yu, X., Zeng, Z., Cao, Y., Young, K. H., & Li, Y. (2023). PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. Journal of Clinical Investigation. https://doi.org/10.1172/jci160456
Vancouver
Yu X, Li W, Liu H, Wang X, Coarfa C, Cheng C, et al. PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. Journal of Clinical Investigation. 2023. doi:10.1172/jci160456
BibTeX
@article{Yu2023,
author = {Yu, Xinfang and Li, Wei and Liu, Haidan and Wang, Xu and Coarfa, Cristian and Cheng, Chao and Yu, Xinlian and Zeng, Zhaoyang and Cao, Ya and Young, Ken H and Li, Yong},
title = {PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination},
journal = {Journal of Clinical Investigation},
year = {2023},
doi = {10.1172/jci160456}
}
EUVIMED